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Edited by Ivan SadowskiAbstract 1a,25-Dihydroxyvitamin D3 (VitD3) increases protein
and gene expression of phospholipase D1 (PLD1), but not
PLD2, in HaCaT human keratinocytes. We show that VitD3
increases PLD1 gene expression through a vitamin D responsive
element (VDRE) on the 5 0 PLD1 promoter (260 bp to 246 bp
from exon 1). Similar results were obtained by transfecting
VitD3 receptor (VDR) into HEK293 cells, which are originally
VitD3-unresponsive. Electrophoresis mobility shift assays
(EMSA) and chromatin immunoprecipitation (CHIP) assays
showed that the complex of VitD3, VDR and retinoid X receptor
a (RXRa) binds to the VDRE and increases PLD1 gene expres-
sion in HaCaT cells.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: 1a,25-Dihydroxyvitamin D3; PLD1 gene
expression; Promoter analysis; VDR; RXRa1. Introduction
The epidermis is primarily composed of keratinocytes
arranged in a layer that recapitulates their programmed life
cycle. Calcium and the active metabolite of vitamin D,
(1a,25(OH)2D3) (VitD3), play an important role in this diﬀer-
entiation process [1]. The observation that VitD3 induces
keratinocyte diﬀerentiation was ﬁrst made by Hosomi et al.
[2] and provided a rationale for the previously unexpected ﬁnd-
ing of VitD3 receptors in the epidermis. It turned out that the
keratinocytes are the site of synthesis and the target of VitD3
[3]. Moreover, VitD3 increases the expression of involucrinAbbreviations: VitD3, 1a,25-dihydroxyvitamin D3; PLD, phospholi-
pase D; VDRE, vitamin D3 responsive element; EMSA, electropho-
resis mobility shift assay; CHIP, chromatin immunoprecipitation;
VDR, vitamin D3 receptor; RXR, retinoid X receptor; RAR, retinoic
acid receptor; PC, phosphatidylcholine; PA, phosphatidic acid; DAG,
diacylglycerol; PKC, protein kinase C
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doi:10.1016/j.febslet.2007.03.073and transglutaminase, leading to enhanced corniﬁed envelope
formation [4].
Two phospholipase D (PLD) isoforms, PLD1 and PLD2,
have been cloned and characterized [5]. PLD1 activity is regu-
lated by a variety of factors including ARF, RhoA, and PKC-
a. PLD2, on the other hand, is considered to be constitutively
active [5]. PLD hydrolyzes phosphatidylcholine (PC) to gener-
ate phosphatidic acid (PA), which can be converted to diacyl-
glycerol (DAG), the regulator of protein kinase C (PKC), via
the action of PA phosphatase.
VitD3 induces enhanced PLD activity by increased expres-
sion of PLD1 in the spinous and granular layers [6]. The
PLD signaling has been thought to mediate late diﬀerentiation
events in epidermal keratinocytes. In HaCaT human keratino-
cyte cells, both the expression of PLD1 and PLD2 mRNA and
the presence of PLD1 protein were reported brieﬂy [7], but the
sequential change in PLD isozymes during VitD3-induced dif-
ferentiation and the regulatory mechanism of PLD1 gene
expression have not been investigated.
Activation of VitD3-induced gene expression is reported to
occur through the nuclear receptors that bind to vitamin D
responsive elements (VDRE) of the promoter [8]. In this re-
port, we reported the molecular mechanism of increased gene
expression via VitD3 of PLD1 but not of PLD2 through the
identiﬁcation of VDRE of the PLD1 promoter region.2. Materials and methods
2.1. Cell lines and reagents
HEK293 cells and a human keratinocyte cell line, HaCaT, were
used. After cells became subconﬂuent, VitD3 (ﬁnal concentration:
250 nM) or calcium (ﬁnal concentration: 8 mM) was added for 48 h.
Human VitD3 receptor (VDR) expression vector was provided by
Dr. G.K. Whitﬁeld (Health Science Center, University of Arizona,
USA).2.2. Western blotting
Western blotting with anti-PLD1 and anti-PLD2 antibodies was
performed as described previously [9].
2.3. Semi-quantitative RT-PCR
Semi-quantitative RT-PCR of human PLD1 and PLD2 was per-
formed as described before [9]. In the preliminary experiments, suitableblished by Elsevier B.V. All rights reserved.
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ampliﬁcation of PLD1 and PLD2 were determined in HaCaT cells. As
the internal control, a GAPDH message was measured. The band
intensities of PLD1 at 28 cycles, PLD2 at 26 cycles and GAPDH at
20 cycles were measured by NIH image version 6. The expression levels
of PLD1 and PLD2 were shown as the ratio of PLD/GAPDH.2.4. Rapid ampliﬁcation of 5 0 cDNA ends (5 0 RACE)
The transcription initiation sites of PLD1 and PLD2 of HaCaT cells
were determined using a Gene Racer Kit (Invitrogen), and primer sets
used were described previously [9].2.5. Preparation of reporter vector containing PLD promoter region
The luciferase vectors containing 5 0 promoter of PLD1 (originally:
1600 bp/Luc, renamed 1592 bp/Luc in the current study) and
PLD2 (originally: 1700 bp/Luc, renamed as 1682 bp/Luc) and their
truncated forms were described previously [9]. Since only 8 bp diﬀer-
ence was observed in the transcription initiation site between SH-
SY5Y cells [9] and HaCaT cells (Fig. 2), the naming of each reporter
vector was slightly modiﬁed from those previously described [9].
Two additional PLD1 truncated mutants (238 bp/Luc and
187 bp/Luc, shown in Fig. 2) were obtained using the PCR-based
method. To introduce a mutation to the VDRE binding motif, the fol-
lowing primer sets were prepared, and PCR was performed using
278 bp/Luc as the template.
Upper primer: 5 0-GGGACGCGTATAGCGAGCATTCCCTA-
AAATTTTGC AAATTTGTTATGAAAC-3 0, in which the Mlu-1
enzyme site is underlined. Boxes indicate the mutated sequence added
to VDRE. The lower primer was GL primer 2 of the pGL3 basic vector
(Promega).2.6. Promoter analysis
HaCaT cells were transfected with 5 lg of reporter plasmid contain-
ing various lengths of PLD1 or PLD2 Luc reporter gene and 2 lg of b-
galactosidase (b-gal) expression vector (Promega) using Lipofectin
(Invitrogen) for 24 h in triplicates. After treating with 250 nM of VitD3
for 48 h, luciferase activity and b-gal activity were measured. Promoter
activity was normalized with the b-gal activity.PLD1
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B2.7. Electrophoresis mobility shift assay (EMSA)
Nuclear extract was prepared from HaCaT cells treated with VitD3
treatment for 48 h. EMSA was performed according to the method de-
scribed previously [9]. For the supershift experiment, anti-VDR (H-
81x, sc-9164x), anti-retinoid X receptor (RXRa; D-20x, sc-553x), or
anti-RARa (C-20, sc-551) antibody (Santa Cruz Biotechnology, Inc.)
was mixed with each nuclear extract for 15 min at room temperature
before incubating with the labeled probes. Sequences of wild and mu-
tant oligos were 5 0-CCCTAGGGTGATGCGGTCGAGTTATG-3 0
(wild type) (265 bp/240 bp from 1st exon) and 5 0-CCCTAAAA-
TTTTGCAAATTTGTTATG-3 0 (mutant type), respectively. VDRE
motif and its mutant were indicated with underlines and double under-
lines, respectively. A probe deleting VDRE was 5 0-CTAATAGCAGC-
GAGCATTCCCTAGTTATG-3 0. Regions adjacent to VDRE were
underlined.PLD2
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Fig. 1. VitD3 induces PLD1 expression: (A) Western blotting of
HaCaT cells stimulated with either VitD3 (250 nM) or CaCl2 (8 mM)
for 48 h using anti-human PLD1, anti-human PLD2, and anti-b-actin
antibodies, respectively. Number on right side indicates respective
molecular weight of each protein and (B) semi-quantitative RT-PCR
analysis was performed as described in Section 2. Cycle # indicates
number of PCR cycles. PLD1/GAPDH and PLD2/GAPDH denote
relative gene expression levels. Values of control HaCaT cell are
designated as 1.0. Results of the representative experiment are shown
from three independent experiments.2.8. Chromatin immunoprecipitation assay (CHIP)
CHIP assay was performed as described previously [9]. HaCaT cells
treated with or without VitD3 for 48 h were used for the cross-linking
with formaldehyde. For the immunoprecipitation, normal rabbit IgG,
anti-VDR, or anti-RXRa antibody (Santa Cruz; ﬁnal concentration,
1 lg/ll) was added and incubated for 4 h at 4 C. After DNA extrac-
tion, the PLD1 promoter region was ampliﬁed by PCR using primers
5 0-AGATATCATAGGCAAAGC-30 (forward) and 5 0-GTTCCTT-
GTTCTCTTTTCC-3 0 (reverse). Primer set for PLD2 promoter region
was 5 0-AGCCCGGCCAACATGGTGAAA3 0 (forward) and 5 0-TCC-
GCCACCACGCCCAGCTAAA-3 0 (reverse). This region (1653 bp
to 1358 bp from exon 1) was selected because only this PLD2 pro-
moter region contained the possible VDRE motives, GAAATCCCTT-
GAACC (TF score: 75%) and GGATCACAAGGTCAA (TF score:
70%) searched by CONSITE (http://mordor.cgb.ki.se/cgi-bin/CON-
SITE/consite).3. Results
3.1. VitD3-induced enhancement of PLD1 but not PLD2
expression of HaCaT cells
In HaCaT cells, PLD2 proteins were constitutively detected
(Fig. 1A). In contrast, PLD1 protein level was raised with
VitD3 treatment. Calcium did not modify expression pattern
in either of them. Semi-quantitative RT-PCR revealed that
the PLD1 message of VitD3-treated HaCaT cells increased
by 3.8-fold (Fig. 1B).
3.2. Increased PLD1 promoter activity of HaCaT cells
induced with VitD3
The 5 0 RACE revealed that the transcription initiation site
of PLD1 of HaCaT cells was 8 bp upstream of the reported
exon 1 of SH-SY5Y cells [9]. By using the 1592 bp PLD1
Luc reporter, a 2.9-fold increase of promoter activity was ob-
served after a 48-h treatment with VitD3 (Fig. 2A). The PLD2
promoter (1682 bp PLD2 Luc) and its truncated forms did
not show VitD3 responsiveness (data not shown). Truncation
of the PLD1 promoter disclosed that the region between
278 bp and 187 bp from the transcription initiation site
was a candidate for further analysis. Further truncation of this
promoter region revealed the minimal requirement of the re-
gion between 278 bp and 238 bp for the most potential
VitD3 responsiveness (Fig. 2B). This small region of PLD1
contains the putative VDRE binding motif with of six base
stretches (GGGTGA and GGTCGA) and with a 3-base spac-
ing (TGC). When a mutation was introduced to this region,
VitD3 responsiveness was lost (Fig. 2C). The involvement of
VDR was conﬁrmed by using HEK 293 cells by transiently
transfecting VDR expression vector. Original HEK293 cells
showed no VitD3 responsiveness in the PLD1 promoter
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Fig. 2. Promoter structure and reporter assay of PLD1. (A) Results of promoter analysis using various 5 0 promoter fragments of PLD1. The +1
indicates transcription initiation site of HaCaT cells (precise data not shown). Asterisk denotes transcription initiation site of SH-SY5Y cells [9].
Relative promoter activity is presented as PLD/b gal. Data of means ± S.D. were obtained from at least three independent experiments. Data of
27 bp/Luc PLD1 were expressed as 1.0. The fold increase by VitD3 treatment is shown at right hand side of the ﬁgures. Signiﬁcant diﬀerence
between VitD3 (+) and () group of each reporter vector transfected cells were indicated with **(P < 0.005 by Student’s t-test). (B) Further analysis of
truncated promoter (from 278 bp to 27 bp) of PLD1. Luciferase vectors were shown on the left. Data are indicated as means ± S.D. obtained
from at least three independent experiments. Value of 27 bp/Luc PLD1 vector is also illustrated as 1.0. VDRE motif located between 278 bp and
238 bp of 5 0 PLD1 promoter was also illustrated. **P < 0.005 by Student’s t-test. (C) Eﬀect of mutant VDRE motif of truncated promoter. Data are
expressed as means ± S.D. obtained from at least three independent experiments. Signiﬁcant diﬀerence between VitD3 (+) and () group of each
reporter vector transfected cells was indicated as **(P < 0.005). 2D PLD1 promoter analysis was performed using HEK293 cells which were
transiently transfected with or without VDR expression vector (1 lg/30 mm plastic dish). After transfection, cells were treated with or without
250 nM of VitD3 for 48 h. Relative promoter activity was presented as PLD/b gal. Data are indicated as means ± S.D. obtained from at least three
independent experiments. Data of 27 bp/Luc PLD1 in VitD3 () group were expressed as 1.0. Statistical signiﬁcance was calculated was between
VDR-transfected HEK cells with VitD3treatment (solid column) and HEK293 without VitD3 treatment (open column) and also between VDR-
transfected HEK with VitD3treatment and HEK293 cells with VitD3 (oblique line). Signiﬁcant diﬀerences are indicated with **(P < 0.005).
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vitamin D3 responsiveness in the PLD1 promoter assay was
recovered, conﬁrming the complex formation of VitD3 and
VDR followed by the binding of this complex to VDRE of
the PLD1 5 0-promoter.
3.3. Interaction of VitD3 with vitamin D3 responsive element
(VDRE) of PLD1 promoter
Fig. 3A illustrates results of EMSA by using HaCaT cell nu-
clear extract with/without VitD3 treatment for 48 h. It was
shown that the intensity of the bands (a and b) was increased
after the VitD3 treatment. Addition of a cold competitor re-
sulted in the disappearance of these two bands in a dose-
dependent manner. In Fig. 3B, a mutant competitor which
contained the same mutation shown in Fig. 2C was used. It
clearly showed that the mutant competitor could not erase
the speciﬁc bands, a and b, suggesting the speciﬁcity of thesetwo bands. An oligo probe with either a mutation (VDRE
Mut) or deletion of VRDE (VDRE Del) showed no shifted-
band (Fig. 3C). We could not explain why a non-speciﬁc band
c did not appear. The possibility might remain that band c is
also a complex between the VDRE motif and some cellular
protein. However, at present, we consider that the band c is
a non-speciﬁc one because it was not competed out by the
wild-type competitor. It has been reported that VitD3 regulates
gene expression through binding to VitD3 receptor (VDR),
which acts as a heterodimer with retinoid RXR [10]. Band a
was decreased and supershifted band a 0 appeared by anti-
VDR antibody. Band b was decreased and supershifted band
b 0 appeared using anti-RXRa antibody but not by anti-RAR
antibody (Fig. 3D). These results provide some insight into
the complicated binding at the VDRE (two probable consen-
sus motives spaced with 3 bp) of the complex of VDR,
RXRa,and VitD3.
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Fig. 3. Characterization of retarded bands in EMSA. (A) Two micrograms of nuclear protein was mixed with 600 fmol of biotin-labeled oligoprobe
described in Section 2. Far left lane denotes no nuclear extract. VitD3-responsive bands are shown as a and b. Cold competitor (·5- to ·40-fold
excess) was added simultaneously with labeled probe. (B) Eﬀect of a mutant competitor. The same experiment was performed except that mutant
competitor as described in Section 2 was used. (C) Eﬀect of a mutation or deletion of VDRE of the probes on EMSA. Nuclear proteins of HaCaT
cells with/without VitD3 for 2 days were used. VDRE wild type (VDREWt), mutant VDRE type (VDREMut) and VDRE-deleted type (VDRE Del)
probe was used, respectively. (D) Supershift experiment. Anti-VDR antibody, anti-RXRa antibody or anti-RARa antibody (ﬁnal concentration of
each: 1 lg/ml) was added to 2 lg of nuclear protein. After 30 min incubation, EMSA was performed.
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by anti-VDR and anti-RXRa antibody
In Fig. 4A, anti-VDR or anti-RXRa antibody but not nor-
mal IgG could immunoprecipitate the VDRE of 5 0-promoter
of PLD1 after VitD3 treatment. On the contrary, no PCR
product was observed using primers designed for PLD2 pro-
moter which covered the most probable region of VDRE
searched by CONSITE (Fig. 4B). These results suggest thatInput
IP Antibody
-349 -213
VDRE motif
Vit D3
Cont
A
C
Anti-VDR AbAnti-RXR Ab
IgG No Ab VDR RXR
1α, 25(OH)2D3
RXR VDR
PLD1
Input
IP Antibody
IgG No Ab VDR RXR
PLD2B
Fig. 4. CHIP assay. (A) CHIP assay was performed using HaCaT cells
treated with (VitD3)/without VitD3 (Cont) for 48 h. Anti-VDR and
anti-RXRa antibody (ﬁnal concentration: 1 lg/ml) was used for
immunoprecipitation. Expected PCR product of PLD1 was 137 bp
covering the 5 0-promoter region between 349 and 213 bp of PLD1
where VDRE binding motif is located. (B) The same experiment as
shown in (A) was performed except that PLD2 speciﬁc primer set was
used as described in Section 2. The expected PCR product was 296 bp.
A schematic illustration of CHIP assay of PLD1 is shown in (C).VitD3 and VDR/RXR complex cannot bind this PLD2 pro-
moter region, which is consistent with VitD3 non-responsive-
ness of PLD2 gene expression. Fig. 4C shows a schematic
illustration of the binding of transcription factors and
VitD3complex and VDRE located in the 5
0 promoter of
PLD1 genome.4. Discussion
VDR, a ligand-dependent transcription factor belonging to
the steroid/thyroid hormone receptor superfamily, regulates
gene expression as a heterodimer with retinoid RXR. Ligand
occupancy of the VDRE leads to the recruitment of a chroma-
tin remodeling complex and the vitamin D-mediated induction
of gene expression [10]. Although the analysis of murine PLD1
and PLD2 gene organization has been reported previously [11],
promoter analysis of PLD isozymes was scarce [9]. Our present
report clearly showed that VitD3 stimulates PLD1 but not
PLD2 gene expression and identiﬁed a VDRE (located from
260 bp to 246 bp from exon 1 of PLD1) in the 5 0-promoter
region of PLD1. Intriguingly, calcium, another stimulator of
keratinocyte diﬀerentiation, did not increase the message and
protein expression of PLD1 in HaCaT cells, although the
involvement of calcium in PLD1 and PLD2 enzyme activation
has been reported using Sf9 cells transfected with PLD expres-
sion vectors [12].
VitD3 induced PLD1 expression in primary keratinocyte [6].
Essential role of PLD was reported in the activation of PKC
[13]. In VitD3-treated HaCaT cells, increased PLD1 expression
might lead to enhanced PA production, which are converted to
1804 R. Kikuchi et al. / FEBS Letters 581 (2007) 1800–1804DAG. DAG activates PKC, which is important to keratino-
cyte diﬀerentiation process [14].
Furthermore, the cotransfection of VDR into HEK293 cells
restored VitD3 responsiveness when it was transfected with
278 bp/Luc but not 187 bp/Luc vector, suggesting the inter-
action of the VDRE motif (GGGTGAtgcGGTCGA) with the
VitD3/VDR complex. The participation of RXRa in the com-
plex was shown in the supershift experiment (Fig. 3D). A num-
ber of natural and synthetic VDREs have been identiﬁed and
these responsive elements consisted of the direct repeat of
two hexameric core binding sites [15] and the VDRE of
PLD1 in the current study partially resembled to those de-
scribed [15]. Although several coactivators are important for
VitD3-induced gene expressions [10], increased VitD3/VDR/
RXRa complex formation and their binding to VDRE may
be a major cause of increased PLD1 gene expression in
VitD3-induced HaCaT cells. Our results help understanding
the regulatory mechanism of PLD1 gene expression in the
keratinocyte diﬀerentiation.
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